About ESSA Pharma
ESSA Pharma is a company based in Vancouver (Canada) founded in 2009 was acquired by Alexis Bio in July 2025. It operates as a HealthTech. ESSA Pharma has raised $16.38 million across 10 funding rounds from investors including Pfizer, Blackstone and Alexis Bio. ESSA Pharma has completed 1 acquisition, including Realm Therapeutics. ESSA Pharma offers products and services including Masofaniten (EPI-7386). ESSA Pharma operates in a competitive market with competitors including Jazz Pharmaceuticals, C4 Therapeutics, Erasca, MiRagen and Mereo BioPharma, among others.
- Headquarter Vancouver, Canada
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Essa Pharma Inc.
-
Annual Revenue
-
Net Profit
$-28.54 M-7as on Sep 30, 2024
-
EBITDA
-
Total Equity Funding
$16.38 M (USD)
in 10 rounds
-
Latest Funding Round
$10 M (USD), Post-IPO
Jan 12, 2021
-
Investors
Pfizer
& 6 more
-
Employee Count
Employee Count
- Investments & Acquisitions
-
Acquired by
Alexis Bio
(Jul 14, 2025)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of ESSA Pharma
ESSA Pharma is a publicly listed company on the NASDAQ with ticker symbol EPIX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of ESSA Pharma
ESSA Pharma offers a comprehensive portfolio of products and services, including Masofaniten (EPI-7386). The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Novel therapy targeting androgen receptor for prostate cancer.
Unlock access to complete
Unlock access to complete
Leadership Team
9 people
Scientific Team
1 people
Finance and Accounting
1 people
Chairman Team
1 people
Unlock access to complete
Funding Insights of ESSA Pharma
ESSA Pharma has successfully raised a total of $16.38M across 10 strategic funding rounds. The most recent funding activity was a Post-IPO round of $10 million completed in January 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 10
- Last Round Post-IPO — $10.0M
-
First Round
First Round
(01 Jul 2014)
- Investors Count 6
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan, 2021 | Amount | Post-IPO - ESSA Pharma | Valuation |
investors |
|
| Jan, 2018 | Amount | Post-IPO - ESSA Pharma | Valuation |
investors |
|
| Jan, 2018 | Amount | Post-IPO - ESSA Pharma | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in ESSA Pharma
ESSA Pharma has secured backing from 7 investors, including institutional and venture fund investors. Prominent investors backing the company include Pfizer, Blackstone and Alexis Bio. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm
|
Founded Year | Domain | Location | |
|
Healthcare ecosystem is supported through investment and innovation by Deerfield.
|
Founded Year | Domain | Location | |
|
Diversified investment management is provided across multiple asset classes.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by ESSA Pharma
ESSA Pharma has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Realm Therapeutics. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Immunomodulatory formulations for the treatment of eye and skin inflammation.
|
1997 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - ESSA Pharma
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Essa Pharma Comparisons
Competitors of ESSA Pharma
ESSA Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, C4 Therapeutics, Erasca, MiRagen and Mereo BioPharma, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
|
| domain | founded_year | HQ Location |
Therapeutics for cancer and rare diseases are developed.
|
|
| domain | founded_year | HQ Location |
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Essa Pharma
Frequently Asked Questions about ESSA Pharma
When was ESSA Pharma founded?
ESSA Pharma was founded in 2009 and raised its 1st funding round 5 years after it was founded.
Where is ESSA Pharma located?
ESSA Pharma is headquartered in Vancouver, Canada. It is registered at Vancouver, British Columbia, Canada.
Who is the current CEO of ESSA Pharma?
David Parkinson is the current CEO of ESSA Pharma.
Is ESSA Pharma a funded company?
ESSA Pharma is a funded company, having raised a total of $16.38M across 10 funding rounds to date. The company's 1st funding round was a Post-IPO of $21M, raised on Jul 01, 2014.
What does ESSA Pharma do?
ESSA Pharma is engaged in the development of novel therapies for prostate cancer treatment. The company operates in the healthcare sector, specifically targeting oncology through innovative approaches. Its lead candidate, masofaniten (EPI-7386), is designed to disrupt the androgen receptor signaling pathway, a key driver of prostate cancer growth. Solutions are developed to complement existing treatments by targeting the N-terminal domain of the androgen receptor, addressing resistance mechanisms in current therapies. Clinical trials, including monotherapy and combination studies, are conducted to evaluate efficacy and safety in patients with castration-resistant prostate cancer.
Who are the top competitors of ESSA Pharma?
ESSA Pharma's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.
What products or services does ESSA Pharma offer?
ESSA Pharma offers Masofaniten (EPI-7386).
Is ESSA Pharma publicly traded?
Yes, ESSA Pharma is publicly traded on NASDAQ under the ticker symbol EPIX.
How many acquisitions has ESSA Pharma made?
ESSA Pharma has made 1 acquisition, including Realm Therapeutics.
Who are ESSA Pharma's investors?
ESSA Pharma has 7 investors. Key investors include Pfizer, Blackstone, Alexis Bio, Omega Funds, and CPRIT.
What is ESSA Pharma's ticker symbol?
The ticker symbol of ESSA Pharma is EPIX on NASDAQ.